How to judge animal models of Parkinson's disease in terms of neuroprotection.
Identifieur interne : 002C25 ( Main/Merge ); précédent : 002C24; suivant : 002C26How to judge animal models of Parkinson's disease in terms of neuroprotection.
Auteurs : E C Hirsch [France]Source :
- Journal of neural transmission. Supplementum [ 0303-6995 ] ; 2006.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Neuroprotective Agents.
- chemical , toxicity : Neurotoxins.
- chemically induced : Parkinson Disease, Secondary.
- drug therapy : Parkinson Disease.
- genetics : Parkinson Disease.
- Animals, Disease Models, Animal, Humans.
Abstract
Ideally, animal models of Parkinson's should reproduce the clinical manifestation of the disease, a loss of some but not all dopaminergic neurons, a loss of some non dopaminergic neurons and alpha-synuclein positive inclusions resembling Lewy bodies. There are at least three ways to develop animal models of PD. The first two are based on the etiology of the disease and consist in 1) reproducing in animals the mutations seen in inherited forms of PD; 2) intoxicating animals with putative environmental toxins causing PD. The last method currently used, which is not exclusive of the first two, is to try to reproduce the molecular or biochemical changes seen post-mortem in the brain of patients with PD. In this review we discuss the advantages and the drawbacks in term of neuroprotection of the currently used models.
PubMed: 17017538
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000F03
- to stream PubMed, to step Curation: 000E63
- to stream PubMed, to step Checkpoint: 000E63
- to stream Ncbi, to step Merge: 000652
- to stream Ncbi, to step Curation: 000652
- to stream Ncbi, to step Checkpoint: 000652
Links to Exploration step
pubmed:17017538Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">How to judge animal models of Parkinson's disease in terms of neuroprotection.</title><author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U679, Hôpital de la Salpêtrière, Université Pierre et Marie Curie-Paris 6, Paris, France. hirsch@ccr.jussieu.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U679, Hôpital de la Salpêtrière, Université Pierre et Marie Curie-Paris 6, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:17017538</idno><idno type="pmid">17017538</idno><idno type="wicri:Area/PubMed/Corpus">000F03</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F03</idno><idno type="wicri:Area/PubMed/Curation">000E63</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E63</idno><idno type="wicri:Area/PubMed/Checkpoint">000E63</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E63</idno><idno type="wicri:Area/Ncbi/Merge">000652</idno><idno type="wicri:Area/Ncbi/Curation">000652</idno><idno type="wicri:Area/Ncbi/Checkpoint">000652</idno><idno type="wicri:doubleKey">0303-6995:2006:Hirsch E:how:to:judge</idno><idno type="wicri:Area/Main/Merge">002C25</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">How to judge animal models of Parkinson's disease in terms of neuroprotection.</title><author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U679, Hôpital de la Salpêtrière, Université Pierre et Marie Curie-Paris 6, Paris, France. hirsch@ccr.jussieu.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U679, Hôpital de la Salpêtrière, Université Pierre et Marie Curie-Paris 6, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Journal of neural transmission. Supplementum</title><idno type="ISSN">0303-6995</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Humans</term><term>Neuroprotective Agents (therapeutic use)</term><term>Neurotoxins (toxicity)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease, Secondary (chemically induced)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Neurotoxins</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Ideally, animal models of Parkinson's should reproduce the clinical manifestation of the disease, a loss of some but not all dopaminergic neurons, a loss of some non dopaminergic neurons and alpha-synuclein positive inclusions resembling Lewy bodies. There are at least three ways to develop animal models of PD. The first two are based on the etiology of the disease and consist in 1) reproducing in animals the mutations seen in inherited forms of PD; 2) intoxicating animals with putative environmental toxins causing PD. The last method currently used, which is not exclusive of the first two, is to try to reproduce the molecular or biochemical changes seen post-mortem in the brain of patients with PD. In this review we discuss the advantages and the drawbacks in term of neuroprotection of the currently used models.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002C25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:17017538
|texte= How to judge animal models of Parkinson's disease in terms of neuroprotection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:17017538" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |